NETEC Resource Library

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Item

Click for External Resource*

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.

Files for Download

Baricitinib HCP factsheet-final.7.28.21.pdfBaricitinib HCP factsheet-final.7.28.21.pdf

Files for Download

Baricitinib Patient factsheet-final.7.28.21.pdfBaricitinib Patient factsheet-final.7.28.21.pdf

Files for Download

Frequently Asked Questions on the Emergency Use Authorization for Baricitinib for Treatment of COVID-19.pdfFrequently Asked Questions on the Emergency Use Authorization for Baricitinib for Treatment of COVID-19.pdf

Files for Download

Baricitinib LOA FINAL 07.28.21.pdfBaricitinib LOA FINAL 07.28.21.pdf

Item Type

Guide

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Share this page:

Was this resource helpful?


Title

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Description

EUA: For emergency use by healthcare providers for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This fact sheet has been updated from the original (11/09/2020) to accommodate changes (7/28/2021).

Read CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19.

Date

2021-07-28

Collection